サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413245

多発性嚢胞腎疾患治療薬の市場：タイプ、治療、診断、流通チャネル、エンドユーザー別-2024-2030年の世界予測

Polycystic Kidney Disease Drugs Market by Type (ADPKD, ARPKD), Treatment (Medication, Surgery), Diagnosis, Distribution Channels, End-User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 199 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
多発性嚢胞腎疾患治療薬の市場：タイプ、治療、診断、流通チャネル、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 199 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

多発性嚢胞腎疾患治療薬市場規模は2023年に5億1,956万米ドルと推定され、2024年には5億5,657万米ドルに達し、CAGR 5.95%で2030年には7億7,882万米ドルに達すると予測されます。

多発性嚢胞腎疾患治療薬の世界市場

主な市場の統計
基準年[2023］ 5億1,956万米ドル
予測年[2024] 5億5,657万米ドル
予測年 [2030] 7億7,882万米ドル
CAGR（%） 5.95%
多発性嚢胞腎疾患治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは多発性嚢胞腎疾患治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、多発性嚢胞腎疾患治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-多発性嚢胞腎疾患治療薬市場の市場規模および予測は？

2-多発性嚢胞腎疾患治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-多発性嚢胞腎疾患治療薬市場における技術動向と規制の枠組みは？

4-多発性嚢胞腎疾患治療薬市場における主要ベンダーの市場シェアは？

5-多発性嚢胞腎疾患治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 人口における慢性腎疾患の有病率
      • 多発性嚢胞腎に関する協力と調査の増加
      • 各国のヘルスケア支出の増加
    • 抑制要因
      • 生産に伴う複雑さ
    • 機会
      • 市場関係者による先進医療の開発
      • 戦略的提携と生産能力拡大のための投資
    • 課題
      • 品質管理に関する問題
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 多発性嚢胞腎疾患治療薬の市場：タイプ別

  • ADPKD
  • ARPKD

第7章 多発性嚢胞腎疾患治療薬の市場治療別

  • 薬
  • 手術

第8章 多発性嚢胞腎疾患治療薬の市場診断別

  • CTスキャン
  • MRI
  • ウルトラサウンド

第9章 多発性嚢胞腎疾患治療薬の市場流通チャネル別

  • 病院薬局
  • 小売薬局

第10章 多発性嚢胞腎疾患治療薬の市場：エンドユーザー別

  • 病院とクリニック
  • 専門クリニック

第11章 南北アメリカの多発性嚢胞腎疾患治療薬の市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域の多発性嚢胞腎疾患治療薬の市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカの多発性嚢胞腎疾患治療薬の市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第15章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Apotex Inc.
    • AstraZeneca PLC
    • Centessa Pharmaceuticals Limited
    • Dr. Reddys Laboratories Ltd.
    • Galapagos NV
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd.
    • Reata Pharmaceuticals Inc.
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • XORTX Therapeutics Inc.
  • 主要な製品ポートフォリオ

第16章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET DYNAMICS
  • FIGURE 7. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 10. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 12. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 14. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 16. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 26. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ADPKD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ARPKD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 9. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 12. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ULTRA SOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 16. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 231. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 232. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-62667ADFA002

[199 Pages Report] The Polycystic Kidney Disease Drugs Market size was estimated at USD 519.56 million in 2023 and expected to reach USD 556.57 million in 2024, at a CAGR 5.95% to reach USD 778.82 million by 2030.

Global Polycystic Kidney Disease Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 519.56 million
Estimated Year [2024] USD 556.57 million
Forecast Year [2030] USD 778.82 million
CAGR (%) 5.95%
Polycystic Kidney Disease Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Polycystic Kidney Disease Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Polycystic Kidney Disease Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Polycystic Kidney Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Apotex Inc., AstraZeneca PLC, Centessa Pharmaceuticals Limited, Dr. Reddys Laboratories Ltd., Galapagos NV, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Polycystic Kidney Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • ADPKD
    • ARPKD
  • Treatment
    • Medication
    • Surgery
  • Diagnosis
    • CT Scan
    • MRI
    • Ultra Sound
  • Distribution Channels
    • Hospital Pharmacy
    • Retail Pharmacy
  • End-User
    • Hospital & Clinics
    • Speciality Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Polycystic Kidney Disease Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Polycystic Kidney Disease Drugs Market?

3. What are the technology trends and regulatory frameworks in the Polycystic Kidney Disease Drugs Market?

4. What is the market share of the leading vendors in the Polycystic Kidney Disease Drugs Market?

5. Which modes and strategic moves are suitable for entering the Polycystic Kidney Disease Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Polycystic Kidney Disease Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic kidney disorders among population
      • 5.1.1.2. Rising collaboration and research on polycystic kidney disease
      • 5.1.1.3. Growing healthcare expenditure in economies
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities associated with the production
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of advanced medications by market players
      • 5.1.3.2. Strategic alliances and investment for capacity expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Issues pertaining to quality management
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Polycystic Kidney Disease Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. ADPKD
  • 6.3. ARPKD

7. Polycystic Kidney Disease Drugs Market, by Treatment

  • 7.1. Introduction
  • 7.2. Medication
  • 7.3. Surgery

8. Polycystic Kidney Disease Drugs Market, by Diagnosis

  • 8.1. Introduction
  • 8.2. CT Scan
  • 8.3. MRI
  • 8.4. Ultra Sound

9. Polycystic Kidney Disease Drugs Market, by Distribution Channels

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Retail Pharmacy

10. Polycystic Kidney Disease Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospital & Clinics
  • 10.3. Speciality Clinics

11. Americas Polycystic Kidney Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Polycystic Kidney Disease Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Polycystic Kidney Disease Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. AbbVie Inc.
    • 15.1.2. Apotex Inc.
    • 15.1.3. AstraZeneca PLC
    • 15.1.4. Centessa Pharmaceuticals Limited
    • 15.1.5. Dr. Reddys Laboratories Ltd.
    • 15.1.6. Galapagos NV
    • 15.1.7. Johnson & Johnson Services, Inc.
    • 15.1.8. Merck & Co., Inc.
    • 15.1.9. Novartis AG
    • 15.1.10. Otsuka Pharmaceutical Co., Ltd.
    • 15.1.11. Reata Pharmaceuticals Inc.
    • 15.1.12. Sanofi S.A.
    • 15.1.13. Teva Pharmaceutical Industries Ltd.
    • 15.1.14. XORTX Therapeutics Inc.
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing